AMENDMENTS TO LB 151

Introduced by Stuthman, 22.

- 1 1. Strike the original sections and all amendments
- 2 thereto and insert the following new sections:
- 3 Section 1. Section 28-405, Reissue Revised Statutes of
- 4 Nebraska, is amended to read:
- 5 28-405 The following are the schedules of controlled
- 6 substances referred to in the Uniform Controlled Substances Act:
- 7 Schedule I
- 8 (a) Any of the following opiates, including their
- 9 isomers, esters, ethers, salts, and salts of isomers, esters, and
- 10 ethers, unless specifically excepted, whenever the existence of
- 11 such isomers, esters, ethers, and salts is possible within the
- 12 specific chemical designation:
- 13 (1) Acetylmethadol;
- 14 (2) Allylprodine;
- 15 (3) Alphacetylmethadol, except levo-alphacetylmethadol
- 16 which is also known as levo-alpha-acetylmethadol, levomethadyl
- 17 acetate, and LAAM;
- 18 (4) Alphameprodine;
- 19 (5) Alphamethadol;
- 20 (6) Benzethidine;
- 21 (7) Betacetylmethadol;
- 22 (8) Betameprodine;
- 23 (9) Betamethadol;

1	(10)	Betaprodine;
2	(11)	Clonitazene;
3	(12)	Dextromoramide;
4	(13)	Difenoxin;
5	(14)	Diampromide;
6	(15)	Diethylthiambutene;
7	(16)	Dimenoxadol;
8	(17)	Dimepheptanol;
9	(18)	Dimethylthiambutene;
10	(19)	Dioxaphetyl butyrate;
11	(20)	Dipipanone;
12	(21)	Ethylmethylthiambutene;
13	(22)	Etonitazene;
14	(23)	<pre>Etoxeridine;</pre>
15	(24)	Furethidine;
16	(25)	Hydroxypethidine;
17	(26)	Ketobemidone;
18	(27)	Levomoramide;
19	(28)	Levophenacylmorphan;
20	(29)	Morpheridine;
21	(30)	Noracymethadol;
22	(31)	Norlevorphanol;
23	(32)	Normethadone;
24	(33)	Norpipanone;
25	(34)	Phenadoxone;
26	(35)	Phenampromide;
27	(36)	Phenomorphan;

```
1
               (37) Phenoperidine;
 2
               (38) Piritramide;
 3
               (39) Proheptazine;
 4
               (40) Properidine;
 5
               (41) Propiram;
 6
               (42) Racemoramide;
 7
               (43) Trimeperidine;
 8
               (44)
                                                   Alpha-methylfentanyl,
 9
    N-(1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl)
                                                         propionanilide,
10
     1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;
11
               (45) Tilidine;
12
               (46)
                                                       3-Methylfentanyl,
    N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide, its
13
14
    optical and geometric isomers, salts, and salts of isomers;
15
               (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its
16
     optical isomers, salts, and salts of isomers;
17
               (48)
                                                                    PEPAP
18
    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine),
19
     1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
                                                                  optical
20
     isomers, salts, and salts of isomers;
21
               (49)
                                            Acetyl-alpha-methylfentanyl,
22
    N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide,
23
     (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide), its
     optical isomers, salts, and salts of isomers;
24
25
               (50)
                                               Alpha-methylthiofentanyl,
26
    N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide,
27
    (N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide),
```

- 1 its optical isomers, salts, and salts of isomers;
- 2 (51) Benzylfentanyl,
- 3 N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
- 4 (N-(1-benzyl-4-piperidyl)-N-phenylpropanamide), its optical
- 5 isomers, salts, and salts of isomers;
- 6 (52) Beta-hydroxyfentanyl,
- 7 N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide,
- 8 (N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide),
- 9 its optical isomers, salts, and salts of isomers;
- 10 (53) Beta-hydroxy-3-methylfentanyl, (other name:
- 11 N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide),
- 12 its optical and geometric isomers, salts, and salts of isomers;
- 13 (54) 3-methylthiofentanyl,
- 14 N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide,
- 15 (N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide),
- 16 its optical and geometric isomers, salts, and salts of isomers;
- 17 (55)
- 18 N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
- 19 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
- 20 (56) Thiofentanyl,
- 21 N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide,
- 22 (N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide), its
- 23 optical isomers, salts, and salts of isomers; and
- 24 (57) Para-fluorofentanyl,
- 25 N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl) propanamide,
- 26 (N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)propanamide),
- 27 its optical isomers, salts, and salts of isomers.

1	(b) Any of the following opium derivatives, their salts,
2	isomers, and salts of isomers, unless specifically excepted,
3	whenever the existence of such salts, isomers, and salts of
4	isomers is possible within the specific chemical designation:
5	(1) Acetorphine;
6	(2) Acetyldihydrocodeine;
7	<pre>(3) Benzylmorphine;</pre>
8	(4) Codeine methylbromide;
9	(5) Codeine-N-Oxide;
10	(6) Cyprenorphine;
11	<pre>(7) Desomorphine;</pre>
12	(8) Dihydromorphine;
13	<pre>(9) Drotebanol;</pre>
14	(10) Etorphine, except hydrochloride salt;
15	(11) Heroin;
16	(12) Hydromorphinol;
17	<pre>(13) Methyldesorphine;</pre>
18	(14) Methyldihydromorphine;
19	(15) Morphine methylbromide;
20	<pre>(16) Morphine methylsulfonate;</pre>
21	(17) Morphine-N-Oxide;
22	(18) Myrophine;
23	(19) Nicocodeine;
24	(20) Nicomorphine;
25	(21) Normorphine;
26	(22) Pholcodine; and
27	(23) Thebacon.

- 1 (c) Any material, compound, mixture, or preparation which
- 2 contains any quantity of the following hallucinogenic substances,
- 3 their salts, isomers, and salts of isomers, unless specifically
- 4 excepted, whenever the existence of such salts, isomers, and salts
- 5 of isomers is possible within the specific chemical designation,
- 6 and, for purposes of this subdivision only, isomer shall include
- 7 the optical, position, and geometric isomers:
- 8 (1) Bufotenine. Trade and other names shall include, but
- 9 are not limited to: 3-(B-Dimethylaminoethyl)-5-hydroxyindole;
- 10 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;
- 11 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin;
- 12 5-hydroxy-N, N-dimethyltryptamine; and mappine;
- 13 (2) Diethyltryptamine. Trade and other names shall
- 14 include, but are not limited to: N,N-diethyltryptamine;
- 15 N,N-Diethyltryptamine; and DET;
- 16 (3) Dimethyltryptamine. Trade and other names shall
- 17 include, but are not limited to: DMT;
- 18 (4) 4-bromo-2,5-dimethoxyamphetamine. Trade
- 19 and other names shall include, but are not limited
- 20 to: 4-bromo-2, 5-dimethoxy-a-methylphenethylamine;
- 21 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; and
- 22 4-bromo-2,5-DMA;
- 23 (5) 4-methoxyamphetamine. Trade and other names shall
- 24 include, but are not limited to: 4-methoxy-a-methyl-phenethylamine;
- 25 4-methoxy-alpha-methylphenethylamine; and paramethoxyamphetamine,
- 26 PMA;
- 27 (6) 4-methyl-2, 5-dimethoxyamphetamine.

MMM-02/11/2009 MMM-02/11/2009

- 1 4-methyl-2,5-dimethoxyamphetamine. Trade and other
- 2 names shall include, but are not limited
- 3 to: 4-methyl-2,5-dimethoxy-a-methylphenethylamine;
- 4 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; DOM; and STP;
- 5 (7) 5-methoxy-N-N, dimethyltryptamine;
- 6 (8) Ibogaine. Trade and other names
- 7 shall include, but are not limited to:
- 8 7-ethyl-6,6B,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyride
- 9 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido
- 10 (1',2':1,2) azepino (5,4-b) indole; and tabernanthe
- 11 Tabernanthe iboga;
- 12 (9) Lysergic acid diethylamide;
- 13 (10) Marijuana;
- 14 (11) Mescaline;
- 15 (12) Peyote. Peyote shall mean all parts of the plant
- 16 presently classified botanically as Lophophora williamsii Lemaire,
- 17 whether growing or not, the seeds thereof, any extract from
- 18 any part of such plant, and every compound, manufacture, salts,
- 19 derivative, mixture, or preparation of such plant or its seeds or
- 20 extracts;
- 21 (13) Psilocybin;
- 22 (14) Psilocyn;
- 23 (15) Tetrahydrocannabinols, including, but not limited
- 24 to, synthetic equivalents of the substances contained in the plant
- 25 or in the resinous extractives of cannabis, sp. or synthetic
- 26 substances, derivatives, and their isomers with similar chemical
- 27 structure and pharmacological activity such as the following: Delta

- 1 1 cis or trans tetrahydrocannabinol and their optical isomers,
- 2 excluding dronabinol in sesame oil and encapsulated in a soft
- 3 gelatin capsule in a drug product approved by the federal Food
- 4 and Drug Administration; Delta 6 cis or trans tetrahydrocannabinol
- 5 and their optical isomers; and Delta 3,4 cis or trans
- 6 tetrahydrocannabinol and its optical isomers. Since nomenclature
- 7 of these substances is not internationally standardized, compounds
- 8 of these structures shall be included regardless of the numerical
- 9 designation of atomic positions covered;
- 10 (16) 3,4-methylenedioxy amphetamine;
- 11 (17) 5-methoxy-3,4-methylenedioxy amphetamine;
- 5-methoxy-3,4-methylenedioxy-amphetamine;
- 13 (18) 3,4,5-trimethoxy amphetamine;
- 14 (19) N-ethyl-3-piperidyl benzilate;
- 15 (20) N-methyl-3-piperidyl benzilate;
- 16 (21) Thiophene analog of phencyclidine. Trade
- 17 and other names shall include, but are not limited to:
- 18 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienyl analog of
- 19 phencyclidine; TPCP; and TCP;
- 20 (22) 2,5-dimethoxyamphetamine. Trade
- 21 and other names shall include, but are not
- 22 limited to: 2,5-dimethoxy-a-methylphenethylamine;
- 23 <u>2,5-dimethoxy-alpha-methylphenethylamine;</u> and 2,5-DMA;
- 24 (23) Hashish or concentrated cannabis;
- 25 (24) Parahexyl. Trade and other names shall include, but
- 26 are not limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,
- 27 9-trimethyl-6H-dibenzo(b,d)pyran; and synhexyl;

1 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran;

- 2 and Synhexyl;
- 3 (25) Ethylamine analog of phencyclidine. Trade
- 4 and other names shall include, but are not limited to:
- 5 N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl)ethylamine;
- 6 N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; and PCE;
- 7 (26) Pyrrolidine analog of phencyclidine. Trade
- 8 and other names shall include, but are not limited to:
- 9 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; and PHP;
- 10 (27) 3,4-methylenedioxymethamphetamine (MDMA), its
- 11 optical, positional, and geometric isomers, salts, and salts of
- 12 isomers;
- 13 (28) 4-bromo-2,5-dimethoxyphenethylamine.
- 14 <u>4-Bromo-2,5-dimethoxyphenethylamine.</u> Some trade or other names:
- 15 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;
- 16 2C-B; and Nexus;
- 17 (29) Alpha-ethyltryptamine. Some trade or other
- 18 names: etryptamine; Monase; alpha-ethyl-lH-indole-3-ethanamine;
- 19 alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
- 20 alpha-ET; and AET;
- 21 (30) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
- 22 (31) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
- 23 (32) Alpha-methyltryptamine, which is also known as AMT;
- 24 and
- 25 (33) 5-Methoxy-N, N-diisopropyltryptamine,
- 26 <u>5-Methoxy-N,N-diisopropyltryptamine,</u> which is also known as
- 27 5-MeO-DIPT.

1 (d) Unless specifically excepted or unless listed in

- 2 another schedule, any material, compound, mixture, or preparation
- 3 which contains any quantity of the following substances having
- 4 a depressant effect on the central nervous system, including its
- 5 salts, isomers, and salts of isomers whenever the existence of
- 6 such salts, isomers, and salts of isomers is possible within the
- 7 specific chemical designation:
- 8 (1) Mecloqualone;
- 9 (2) Methagualone; and
- 10 (3) Gamma-hydroxybutyric acid. Gamma-Hydroxybutyric
- 11 Acid. Some other names include: GHB; gamma-hydroxybutyrate;
- 12 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; and
- 13 sodium oxybutyrate. Gamma-hydroxybutyrate; 4-Hydroxybutyrate;
- 14 4-Hydroxybutanoic Acid; Sodium Oxybate; and Sodium Oxybutyrate.
- 15 (e) Unless specifically excepted or unless listed in
- 16 another schedule, any material, compound, mixture, or preparation
- 17 which contains any quantity of the following substances having
- 18 a stimulant effect on the central nervous system, including its
- 19 salts, isomers, and salts of isomers:
- 20 (1) Fenethylline;
- 21 (2) N-ethylamphetamine;
- 22 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
- 23 and or 4,5-dihydro-5-phenyl-2-oxazolamine;
- 24 (4) Cathinone; 2-amino-1-phenyl-1-propanone;
- 25 alpha-aminopropiophenone; 2-aminopropiophenone; and norephedrone;
- 26 (5) Methcathinone, its salts, optical isomers,
- 27 and salts of optical isomers. Some other names:

- 1 2-(methylamino)-propiophenone; alpha-(methylamino)propiophenone;
- 2 2-(methylamino)-1-phenylpropan-1-one;
- 3 alpha-N-methylaminopropiophenone; methylcathinone;
- 4 monomethylpropion; ephedrone; N-methylcathinone; AL-464; AL-422;
- 5 AL-463; and UR1432;
- 6 (6) (+/-) cis-4-methylaminorex; and
- 7 (+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine;
- 8 and
- 9 (7) N,N-dimethylamphetamine;
- 10 N,N-alpha-trimethyl-benzeneethanamine; and
- 11 N, N-alpha-trimethylphenethylamine.
- 12 (f) Any controlled substance analogue to the extent
- 13 intended for human consumption.
- 14 Schedule II
- 15 (a) Any of the following substances except those narcotic
- 16 drugs listed in other schedules whether produced directly or
- 17 indirectly by extraction from substances of vegetable origin,
- 18 independently by means of chemical synthesis, or by combination of
- 19 extraction and chemical synthesis:
- 20 (1) Opium and opiate, and any salt, compound, derivative,
- 21 or preparation of opium or opiate, excluding apomorphine,
- 22 buprenorphine, thebaine-derived butorphanol, dextrorphan,
- 23 nalbuphine, nalmefene, naloxone, and naltrexone and their
- 24 salts, but including the following:
- 25 (i) Raw opium;
- 26 (ii) Opium extracts;
- 27 (iii) Opium fluid;

1 (iv) Powdered opium; 2 (v) Granulated opium; (vi) Tincture of opium; 3 (vii) Codeine; 4 5 (viii) Ethylmorphine; (ix) Etorphine hydrochloride; 6 7 (x) Hydrocodone; (xi) Hydromorphone; 8 (xii) Metopon; 9 10 (xiii) Morphine; 11 (xiv) Oxycodone; 12 (xv) Oxymorphone; 13 (xvi) Oripavine; 14 (xvii) Thebaine; and 15 (xviii) Dihydroetorphine; (2) Any salt, compound, derivative, or preparation 16 17 thereof which is chemically equivalent to or identical with any of 18 the substances referred to in subdivision (1) of this subdivision, 19 except that these substances shall not include the isoquinoline 20 alkaloids of opium; 21 (3) Opium poppy and poppy straw; 22 (4) Coca leaves and any salt, compound, derivative, or 23 preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent to or 24 25 identical with any of these substances, including cocaine and its salts, optical isomers, and salts of optical isomers, except 26 27 that the substances shall not include decocainized coca leaves or

1 extractions which do not contain cocaine or ecgonine; and

- 2 (5) Concentrate of poppy straw, the crude extract of
- 3 poppy straw in either liquid, solid, or powder form which contains
- 4 the phenanthrene alkaloids of the opium poppy.
- 5 (b) Unless specifically excepted or unless in another
- 6 schedule any of the following opiates, including their isomers,
- 7 esters, ethers, salts, and salts of their isomers, esters, and
- 8 ethers whenever the existence of such isomers, esters, ethers,
- 9 and salts is possible within the specific chemical designation,
- 10 dextrorphan excepted:
- 11 (1) Alphaprodine;
- 12 (2) Anileridine;
- 13 (3) Bezitramide;
- 14 (4) Diphenoxylate;
- 15 (5) Fentanyl;
- 16 (6) Isomethadone;
- 17 (7) Levomethorphan;
- 18 (8) Levorphanol;
- 19 (9) Metazocine;
- 20 (10) Methadone;
- 21 (11) Methadone-Intermediate, Methadone-intermediate,
- 22 4-cyano-2-dimethylamino-4,4-diphenyl butane;
- 23 (12) Moramide-intermediate,
- 24 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;
- 25 (13) Pethidine or meperidine;
- 26 (14) Pethidine-Intermediate-A,
- 27 4-cyano-1-methyl-4-phenylpiperidine;

1 (15) Pethidine-Intermediate-B,

- 2 ethyl-4-phenylpiperidine-4-carboxylate;
- 3 (16) Pethidine-Intermediate-C,
- 4 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 5 (17) Phenazocine;
- 6 (18) Piminodine;
- 7 (19) Racemethorphan;
- 8 (20) Racemorphan;
- 9 (21) Dihydrocodeine;
- 10 (22) Bulk propoxyphene <u>Dextropropoxyphene</u> in nondosage
- 11 forms;
- 12 (23) Sufentanil;
- 13 (24) Alfentanil;
- 14 (25) Levo-alphacetylmethadol which is also known as
- 15 levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
- 16 (26) Carfentanil; and
- 17 (27) Remifentanil.
- 18 (c) Any material, compound, mixture, or preparation
- 19 which contains any quantity of the following substances having
- 20 a potential for abuse associated with a stimulant effect on the
- 21 central nervous system:
- 22 (1) Amphetamine, its salts, optical isomers, and salts of
- 23 its optical isomers;
- 24 (2) Phenmetrazine and its salts;
- 25 (3) Methamphetamine, its salts, isomers, and salts of its
- 26 isomers; and
- 27 (4) Methylphenidate.

1 (d) Any material, compound, mixture, or preparation which contains any quantity of the following substances having 2 3 a potential for abuse associated with a depressant effect on the central nervous system, including their salts, isomers, and salts 4 5 of isomers whenever the existence of such salts, isomers, and salts 6 of isomers is possible within the specific chemical designations: 7 (1) Amobarbital; 8 (2) Secobarbital; (3) Pentobarbital; 9 10 (4) Phencyclidine; and 11 (5) Glutethimide. 12 (e) Hallucinogenic substances known as: 13 Nabilone. Another (1) name for 14 nabilone: (+/-)-trans-3-(1,1-dimethylheptyl)-15 6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one-16 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one. 17 (f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation 18 which contains any quantity of the following substances: 19 20 (1) Immediate precursor amphetamine to and 21 methamphetamine: Phenylacetone. Trade and other names shall 22 include, but are not limited to: Phenyl-2-propanone; P2P; benzyl 23 methyl ketone; and methyl benzyl ketone; or 24 (2) Immediate precursors to phencyclidine, PCP: (i) 1-phenylcyclohexylamine; or 25 26 (ii) 1-piperidinocyclohexanecarbonitrile, PCC. 27 Schedule III

1 (a) Any material, compound, mixture, or preparation which contains any quantity of the following substances having 2 a potential for abuse associated with a stimulant effect on the 3 central nervous system, including their salts, isomers, whether 4 5 optical, position, or geometric, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is 6 7 possible within the specific chemical designation: 8 (1) Benzphetamine; 9 (2) Chlorphentermine; 10 (3) Clortermine; and 11 (4) Phendimetrazine. 12 (b) Any material, compound, mixture, or preparation which contains any quantity of the following substances having 13 14 a potential for abuse associated with a depressant effect on the 15 central nervous system: (1) Any substance which contains any quantity of a 16 17 derivative of barbituric acid or any salt of a derivative of barbituric acid, except those substances which are specifically 18 listed in other schedules of this section; 19 20 (2) Chlorhexadol; 21 (3) Lysergic acid; 22 (4) Lysergic acid amide; 23 (5) Methyprylon; 24 (6) Sulfondiethylmethane; (7) Sulfonethylmethane; 25 26 (8) Sulfonmethane; 27 (9) Nalorphine;

1 (10) Any compound, mixture, or preparation containing

- 2 amobarbital, secobarbital, pentobarbital, or any salt thereof and
- 3 one or more other active medicinal ingredients which are not listed
- 4 in any schedule;
- 5 (11) Any suppository dosage form containing amobarbital,
- 6 secobarbital, pentobarbital, or any salt of any of these drugs and
- 7 approved by the Food and Drug Administration for marketing only as
- 8 a suppository;
- 9 (12) Any drug product containing gamma-hydroxybutyric
- 10 acid, including its salts, isomers, and salts of isomers, for which
- 11 an application is approved under section 505 of the Federal Food,
- 12 Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on
- 13 July 20, 2002;
- 14 (13) Ketamine, its salts, isomers, and
- 15 salts of isomers. Some other names for ketamine:
- 16 (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone; and
- 17 (14) Tiletamine and zolazepam or any salt thereof.
- 18 Trade or other names for a tiletamine-zolazepam combination
- 19 product shall include, but are not limited to: telazol. Trade
- 20 or other names for tiletamine shall include, but are not
- 21 limited to: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Trade or
- 22 other names for zolazepam shall include, but are not limited
- 23 to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)
- 24 (1,4)-diazepin-7(1H)-one, and flupyrazapon.
- 25 (c) Unless specifically excepted or unless listed in
- 26 another schedule:
- 27 (1) Any material, compound, mixture, or preparation

1 containing limited quantities of any of the following narcotic

- 2 drugs, or any salts calculated as the free anhydrous base or
- 3 alkaloid, in limited quantities as set forth below:
- 4 (i) Not more than one and eight-tenths grams of codeine
- 5 per one hundred milliliters or not more than ninety milligrams per
- 6 dosage unit, with an equal or greater quantity of an isoquinoline
- 7 alkaloid of opium;
- 8 (ii) Not more than one and eight-tenths grams of codeine
- 9 per one hundred milliliters or not more than ninety milligrams per
- 10 dosage unit, with one or more active, nonnarcotic ingredients in
- 11 recognized therapeutic amounts;
- 12 (iii) Not more than three hundred milligrams of
- 13 dihydrocodeinone which is also known as hydrocodone per one hundred
- 14 milliliters or not more than fifteen milligrams per dosage unit,
- 15 with a fourfold or greater quantity of an isoquinoline alkaloid of
- 16 opium;
- 17 (iv) Not more than three hundred milligrams of
- 18 dihydrocodeinone which is also known as hydrocodone per one hundred
- 19 milliliters or not more than fifteen milligrams per dosage unit,
- 20 with one or more active, nonnarcotic ingredients in recognized
- 21 therapeutic amounts;
- 22 (v) Not more than one and eight-tenths grams of
- 23 dihydrocodeine per one hundred milliliters or not more than ninety
- 24 milligrams per dosage unit, with one or more active, nonnarcotic
- 25 ingredients in recognized therapeutic amounts;
- 26 (vi) Not more than three hundred milligrams of
- 27 ethylmorphine per one hundred milliliters or not more than fifteen

1 milligrams per dosage unit, with one or more active, nonnarcotic

- 2 ingredients in recognized therapeutic amounts;
- 3 (vii) Not more than five hundred milligrams of opium per
- 4 one hundred milliliters or per one hundred grams, or not more than
- 5 twenty-five milligrams per dosage unit, with one or more active,
- 6 nonnarcotic ingredients in recognized therapeutic amounts; and
- 7 (viii) Not more than fifty milligrams of morphine per
- 8 one hundred milliliters or per one hundred grams with one or more
- 9 active, nonnarcotic ingredients in recognized therapeutic amounts;
- 10 and
- 11 (2) Any material, compound, mixture, or preparation
- 12 containing any of the following narcotic drug or its salts, as
- 13 set forth below:
- 14 (i) Buprenorphine.
- 15 (d) Unless contained on the administration's list of
- 16 exempt anabolic steroids as the list existed on June 1, 2007,
- 17 any anabolic steroid, which shall include any material, compound,
- 18 mixture, or preparation containing any quantity of the following
- 19 substances, including its salts, isomers, and salts of isomers
- 20 whenever the existence of such salts of isomers is possible within
- 21 the specific chemical designation:
- 22 (1) Boldenone;
- 23 (2) Chlorotestosterone (4-chlortestosterone);
- 24 (3) Clostebol;
- 25 (4) Dehydrochlormethyltestosterone;
- 26 <u>Dehydrochloromethyltestosterone;</u>
- 27 (5) Dihydrotestosterone (4-dihydrotestosterone);

AM300 LB151 MMM-02/11/2009 MMM-02/11/2009

1	(6) Drostanolone;	
2	(7) Ethylestrenol;	
3	(8) Fluoxymesterone;	
4	<pre>(9) Formebulone (formebolone);</pre>	
5	(10) Mesterolone;	
6	(11) Methandienone;	
7	(12) Methandranone;	
8	<pre>(13) Methandriol;</pre>	
9	(14) Methandrostenolone;	
10	(15) Methenolone;	
11	<pre>(16) Methyltestosterone;</pre>	
12	(17) Mibolerone;	
13	(18) Nandrolone;	
14	(19) Norethandrolone;	
15	(20) Oxandrolone;	
16	(21) Oxymesterone;	
17	(22) Oxymetholone;	
18	(23) Stanolone;	
19	(24) Stanozolol;	
20	(25) Testolactone;	
21	(26) Testosterone;	
22	(27) Trenbolone; and	
23	(28) Any salt, ester, or isomer <u>ether</u>	of a drug or
24	substance described or listed in this subdivision	if the salt,
25	ester, or isomer ether promotes muscle growth.	
26	(e) Hallucinogenic substances known as:	
27	(1) Dronabinol, synthetic, in sesame oil ar	d encapsulated

1 in a soft gelatin capsule in a Food and Drug Administration

- 2 approved drug product. Some other names for dronabinol are
- 3 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
- 4 (b,d)pyran-1-ol (b,d)pyran-1-ol or
- 5 (-)-delta-9-(trans)-tetrahydrocannabinol.
- 6 Schedule IV
- 7 (a) Any material, compound, mixture, or preparation which
- 8 contains any quantity of the following substances, including their
- 9 salts, isomers, and salts of isomers whenever the existence of
- 10 such salts, isomers, and salts of isomers is possible within the
- 11 specific chemical designation:
- 12 (1) Barbital;
- 13 (2) Chloral betaine;
- 14 (3) Chloral hydrate;
- 15 (4) Chlordiazepoxide, but not including librax
- 16 (chlordiazepoxide hydrochloride and clindinium bromide) or menrium
- 17 (chlordiazepoxide and water soluble esterified estrogens);
- 18 (5) Clonazepam;
- 19 (6) Clorazepate;
- 20 (7) Diazepam;
- 21 (8) Ethchlorvynol;
- 22 (9) Ethinamate;
- 23 (10) Flurazepam;
- 24 (11) Mebutamate;
- 25 (12) Meprobamate;
- 26 (13) Methohexital;
- 27 (14) Methylphenobarbital;

AM300 LB151 MMM-02/11/2009 MMM-02/11/2009

) Oxazepam;
) Paraldehyde;
) Petrichloral;
) Phenobarbital;
) Prazepam;
) Alprazolam;
) Bromazepam;
) Camazepam;
) Clobazam;
) Clotiazepam;
) Cloxazolam;
) Delorazepam;
) Estazolam;
) Ethyl loflazepate;
) Fludiazepam;
) Flunitrazepam;
) Halazepam;
) Haloxazolam;
) Ketazolam;
) Loprazolam;
) Lorazepam;
) Lormetazepam;
) Medazepam;
) Nimetazepam;
) Nitrazepam;
) Nordiazepam;
) Oxazolam;

1 (42) Pinazepam; 2 (43) Temazepam; (44) Tetrazepam; 3 (45) Triazolam; 4 5 (46) Midazolam; 6 (47) Quazepam; 7 (48) Zolpidem; (49) Dichloralphenazone; and 8 (50) Zaleplon. 9 10 (b) Any material, compound, mixture, or preparation which 11 contains any quantity of the following substance, including its 12 salts, isomers, whether optical, position, or geometric, and salts 13 of such isomers, whenever the existence of such salts, isomers, and 14 salts of isomers is possible: Fenfluramine. 15 (c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation 16 17 which contains any quantity of the following substances having a stimulant effect on the central nervous system, including their 18 salts, isomers, whether optical, position, or geometric, and salts 19 20 of such isomers whenever the existence of such salts, isomers, 21 and salts of isomers is possible within the specific chemical 22 designation: 23 (1) Diethylpropion; 24 (2) Phentermine; (3) Pemoline, including organometallic complexes and 25 26 chelates thereof;

(4) Mazindol;

1 (5) Pipradrol;

- 2 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);
- 3 (7) Cathine. Another name for cathine is
- 4 ((+)-norpseudoephedrine);
- 5 (8) Fencamfamin;
- 6 (9) Fenproporex;
- 7 (10) Mefenorex;
- 8 (11) Modafinil; and
- 9 (12) Sibutramine.
- 10 (d) Unless specifically excepted or unless listed in
- 11 another schedule, any material, compound, mixture, or preparation
- 12 which contains any quantity of the following narcotic drugs, or
- 13 their salts or isomers calculated as the free anhydrous base or
- 14 alkaloid, in limited quantities as set forth below:
- 15 (1) Propoxyphene <u>Dextropropoxyphene</u> in manufactured
- 16 dosage forms; and
- 17 (2) Not more than one milligram of difenoxin and not less
- 18 than twenty-five micrograms of atropine sulfate per dosage unit.
- 19 (e) Unless specifically excepted or unless listed in
- 20 another schedule, any material, compound, mixture, or preparation
- 21 which contains any quantity of the following substance, including
- 22 its salts: Pentazocine.
- 23 (f) Unless specifically excepted or unless listed in
- 24 another schedule, any material, compound, mixture, or preparation
- 25 which contains any quantity of the following substance, including
- 26 its salts, isomers, and salts of such isomers: Butorphanol.
- 27 (g) (1) Unless specifically excepted or unless listed in

AM300 LB151 MMM-02/11/2009

another schedule, any material, compound, mixture, or preparation

AM300

LB151

MMM-02/11/2009

- 2 which contains any quantity of the following substance, including
- 3 its salts, optical isomers, and salts of such optical isomers:
- 4 Ephedrine.

1

5 (2) The following drug products containing ephedrine, its salts, optical isomers, and salts of such optical isomers, 6 7 are excepted from subdivision (g)(1) of Schedule IV if they may 8 lawfully be sold over the counter without a prescription under 9 the Federal Food, Drug, and Cosmetic Act, as the act existed on 10 September 1, 2001; (A) are stored behind a counter, in an area not 11 accessible to customers, or in a locked case so that a customer 12 needs assistance from an employee to access the drug product; 13 (B) are sold by a person, eighteen years of age or older, in 14 the course of his or her employment to a customer eighteen years of age or older with the following restrictions: No customer 15 shall be allowed to purchase, receive, or otherwise acquire 16 17 more than three and six-tenths grams of ephedrine base during 18 a twenty-four-hour period; no customer shall purchase, receive, or 19 otherwise acquire more than nine grams of ephedrine base during a thirty-day period; and the customer shall display a valid 20 21 driver's or operator's license, a Nebraska state identification 22 card, a military identification card, an alien registration card, or a passport as proof of identification; (C) are labeled and 23 24 marketed in a manner consistent with the pertinent OTC Tentative 25 Final or Final Monograph; (D) are manufactured and distributed for 26 legitimate medicinal use in a manner that reduces or eliminates 27 the likelihood of abuse; and (E) are not marketed, advertised, or

1 represented in any manner for the indication of stimulation, mental

- 2 alertness, euphoria, ecstasy, a buzz or high, heightened sexual
- 3 performance, or increased muscle mass:
- 4 (A) (i) Primatene Tablets;
- 5 (B) (ii) Bronkaid Dual Action Caplets; and
- 6 (C) (iii) Pazo Hemorrhoidal Ointment.
- 7 (3) Food and dietary supplements described in 21 U.S.C.
- 8 321, as such section existed on September 1, 2001, containing
- 9 ephedrine, including its salts, optical isomers, and salts of such
- 10 optical isomers, are excepted from subdivision (g)(1) of Schedule
- 11 IV if:
- 12 (A) They are labeled in a manner consistent with section
- 13 28-448 and bear the statements: "This statement has not been
- 14 evaluated by the Food and Drug Administration. This product is not
- 15 intended to diagnose, treat, cure, or prevent any disease.";
- 16 (B) Any dosage form of the food or dietary supplements
- 17 (i) does not contain any hydrochloride or sulfate salts of
- 18 ephedrine alkaloids, (ii) does not contain more than twenty-five
- 19 milligrams of ephedrine alkaloids, and (iii) does not contain
- 20 ephedrine alkaloids in excess of five percent of the total capsule
- 21 weight;
- 22 (C) They are not marketed, advertised, or represented in
- 23 any manner for the indication of stimulation, mental alertness,
- 24 euphoria, ecstasy, a buzz or high, heightened sexual performance,
- 25 or increased muscle mass; and
- 26 (D) Analysis of the product is provided to the department
- 27 to ensure that the product meets the requirements of subdivision

- 1 $\frac{(g)(3)(B)}{of}$ of Schedule IV.
- 2 Schedule V
- 3 (a) Any compound, mixture, or preparation containing any
- 4 of the following limited quantities of narcotic drugs or salts
- 5 calculated as the free anhydrous base or alkaloid, which shall
- 6 include one or more nonnarcotic active medicinal ingredients in
- 7 sufficient proportion to confer upon the compound, mixture, or
- 8 preparation valuable medicinal qualities other than those possessed
- 9 by the narcotic drug alone:
- 10 (1) Not more than two hundred milligrams of codeine per
- 11 one hundred milliliters or per one hundred grams;
- 12 (2) Not more than one hundred milligrams of
- 13 dihydrocodeine per one hundred milliliters or per one hundred
- 14 grams;
- 15 (3) Not more than one hundred milligrams of ethylmorphine
- 16 per one hundred milliliters or per one hundred grams;
- 17 (4) Not more than two and five-tenths milligrams of
- 18 diphenoxylate and not less than twenty-five micrograms of atropine
- 19 sulfate per dosage unit;
- 20 (5) Not more than one hundred milligrams of opium per one
- 21 hundred milliliters or per one hundred grams; and
- 22 (6) Not more than five-tenths milligram of difenoxin and
- 23 not less than twenty-five micrograms of atropine sulfate per dosage
- 24 unit.
- 25 (b) Unless specifically exempted or excluded or unless
- 26 listed in another schedule, any material, compound, mixture, or
- 27 preparation which contains any quantity of the following substances

1 having a stimulant effect on the central nervous system, including

- 2 its salts, isomers, and salts of isomers: Pyrovalerone.
- 3 Sec. 2. Section 28-456, Reissue Revised Statutes of
- 4 Nebraska, is amended to read:
- 5 28-456 (1) Any drug products containing
- 6 phenylpropanolamine, pseudoephedrine, or their salts, optical
- 7 isomers, or salts of such optical isomers may be sold without a
- 8 prescription only if they are:
- 9 (a) Labeled and marketed in a manner consistent with the
- 10 pertinent OTC Tentative Final or Final Monograph;
- 11 (b) Manufactured and distributed for legitimate medicinal
- 12 use in a manner that reduces or eliminates the likelihood of abuse;
- 13 (c) Packaged as follows:
- 14 (i) Except for liquids, sold in package sizes of not
- 15 more than three and six-tenths grams of pseudoephedrine base or
- 16 three and six-tenths grams of phenylpropanolamine base, in blister
- 17 packs, each blister containing not more than two dosage units, or
- 18 if the use of blister packs is technically infeasible, in unit dose
- 19 packets or pouches; and
- 20 (ii) For liquids, sold in package sizes of not more than
- 21 three and six-tenths grams of pseudoephedrine base or three and
- 22 six-tenths grams of phenylpropanolamine base;
- 23 (d) Sold by a person, eighteen years of age or older, in
- 24 the course of his or her employment to a customer, eighteen years
- 25 of age or older, with the following restrictions:
- 26 (i) No customer shall be allowed to purchase, receive,
- 27 or otherwise acquire more than three and six-tenths grams

1 of pseudoephedrine base or three and six-tenths grams of

- 2 phenylpropanolamine base during a twenty-four-hour period;
- 3 (ii) No customer shall purchase, receive, or otherwise
- 4 acquire more than nine grams of pseudoephedrine base or nine grams
- 5 of phenylpropanolamine base during a thirty-day period; and
- 6 (iii) The customer shall display a valid driver's
- 7 or operator's license, a Nebraska state identification card, a
- 8 military identification card, an alien registration card, or a
- 9 passport as proof of identification; and
- 10 (e) Stored behind a counter, in an area not accessible to
- 11 customers, or in a locked case so that a customer needs assistance
- 12 from an employee to access the drug product. 7 except that this
- 13 requirement does not apply to liquid pediatric formulations. For
- 14 the purposes of this subdivision, liquid pediatric formulation
- 15 means a liquid formulation with pseudoephedrine doses of fifteen
- 16 milligrams or less that is manufactured and marketed for children
- 17 twelve years of age or younger. If it is documented by a
- 18 law enforcement agency to the Nebraska State Patrol that a
- 19 liquid pediatric formulation has been found at a methamphetamine
- 20 manufacturing site, the patrol shall present the documentation to
- 21 the chief medical officer, as described in section 81-3115, who
- 22 shall issue an order removing the exemption.
- 23 (2) Any person who sells drug products in violation
- 24 of this section may be subject to a civil penalty of fifty
- 25 dollars per day, and for a second or any subsequent violation,
- 26 the penalty may be one hundred dollars per day. Any such drug
- 27 products shall be seized and destroyed upon the finding of a

1 violation of this section. The department, in conjunction with

- 2 the Attorney General, the Nebraska State Patrol, and local law
- 3 enforcement agencies, shall have authority to make inspections
- 4 and investigations to enforce this section. In addition, the
- 5 department may seek injunctive relief for suspected violations of
- 6 this section.
- 7 Sec. 3. Section 28-456.01, Reissue Revised Statutes of
- 8 Nebraska, is amended to read:
- 9 28-456.01 No person shall purchase, receive, or otherwise
- 10 acquire, other than wholesale acquisition by a retail business
- 11 in the normal course of its trade or business, any drug product
- 12 containing more than one thousand four hundred forty milligrams
- 13 three and six-tenths grams of pseudoephedrine base or one thousand
- 14 four hundred forty milligrams three and six-tenths grams of
- 15 phenylpropanolamine base during a twenty-four-hour period unless
- 16 purchased pursuant to a medical order. Any person who violates this
- 17 section shall be guilty of an infraction as defined in section
- 18 29-431.
- 19 Sec. 4. Original sections 28-405, 28-456, and 28-456.01,
- 20 Reissue Revised Statutes of Nebraska, are repealed.
- 21 Sec. 5. The following sections are outright repealed:
- 22 Sections 28-448 and 28-454, Reissue Revised Statutes of Nebraska.